Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?

The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in health...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Sudhir, Bhandari, Sudhir, Mehta, Shaurya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836824/
https://www.ncbi.nlm.nih.gov/pubmed/32777441
http://dx.doi.org/10.1016/j.jgar.2020.07.022
_version_ 1783642828577964032
author Mehta, Sudhir
Bhandari, Sudhir
Mehta, Shaurya
author_facet Mehta, Sudhir
Bhandari, Sudhir
Mehta, Shaurya
author_sort Mehta, Sudhir
collection PubMed
description The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in healthy individuals and a recent observational study demonstrating benefits of HCQ prophylaxis in terms of a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the health-care workers (HCWs) with the intake of six or more doses of HCQ prophylaxis as per the guidelines of the National Task Force for COVID-19 in India. Hence, pre-exposure prophylaxis with HCQ in appears to be a reasonable strategy in the current scenario for prevention of SARS-CoV-2 infection in healthy HCWs.
format Online
Article
Text
id pubmed-7836824
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.
record_format MEDLINE/PubMed
spelling pubmed-78368242021-01-26 Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection? Mehta, Sudhir Bhandari, Sudhir Mehta, Shaurya J Glob Antimicrob Resist Short Communication The potentiality of Hydroxychloroquine (HCQ) for pre-exposure prophylaxis against SARS-CoV-2 has not been explored in randomized controlled trials. However, there is rationale behind this potentiality in terms of demonstrated in-vitro effect of HCQ against SARS-CoV-2, safety profile of HCQ in healthy individuals and a recent observational study demonstrating benefits of HCQ prophylaxis in terms of a significant reduction (>80%) in the odds of SARS-CoV-2 infection in the health-care workers (HCWs) with the intake of six or more doses of HCQ prophylaxis as per the guidelines of the National Task Force for COVID-19 in India. Hence, pre-exposure prophylaxis with HCQ in appears to be a reasonable strategy in the current scenario for prevention of SARS-CoV-2 infection in healthy HCWs. The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy. 2020-09 2020-08-07 /pmc/articles/PMC7836824/ /pubmed/32777441 http://dx.doi.org/10.1016/j.jgar.2020.07.022 Text en © 2020 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Mehta, Sudhir
Bhandari, Sudhir
Mehta, Shaurya
Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
title Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
title_full Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
title_fullStr Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
title_full_unstemmed Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
title_short Why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against SARS-CoV-2 infection?
title_sort why is pre-exposure prophylaxis with hydroxychloroquine a safe and rationale approach against sars-cov-2 infection?
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836824/
https://www.ncbi.nlm.nih.gov/pubmed/32777441
http://dx.doi.org/10.1016/j.jgar.2020.07.022
work_keys_str_mv AT mehtasudhir whyispreexposureprophylaxiswithhydroxychloroquineasafeandrationaleapproachagainstsarscov2infection
AT bhandarisudhir whyispreexposureprophylaxiswithhydroxychloroquineasafeandrationaleapproachagainstsarscov2infection
AT mehtashaurya whyispreexposureprophylaxiswithhydroxychloroquineasafeandrationaleapproachagainstsarscov2infection

Ejemplares similares